Literature DB >> 16895484

Heparin modulation of human plasma kallikrein on different substrates and inhibitors.

Andrezza J Gozzo1, Viviane A Nunes, Ilana Cruz-Silva, Adriana K Carmona, Helena B Nader, Adelaide Faljoni-Alario, Misako U Sampaio, Mariana S Araújo.   

Abstract

The interplay of different proteases and glycosaminoglycans is able to modulate the activity of the enzymes and to affect their structures. Human plasma kallikrein (huPK) is a proteolytic enzyme involved in intrinsic blood clotting, the kallikrein-kinin system and fibrinolysis. We investigated the effect of heparin on the action, inhibition and secondary structure of huPK. The catalytic efficiency for the hydrolysis of substrates by huPK was determined by Michaelis-Menten kinetic plots: 5.12x10(4) M-1 s-1 for acetyl-Phe-Arg-p-nitroanilide, 1.40x10(5) M-1 s-1 for H-D-Pro-Phe-Arg-p-nitroanilide, 2.25x10(4) M-1 s-1 for Abz-Gly-Phe-Ser-Pro-Phe-Arg-Ser-Ser-Arg-Gln-EDDnp, 4.24x10(2)M-1 s-1 for factor XII and 5.58x10(2) M-1 s-1 for plasminogen. Heparin reduced the hydrolysis of synthetic substrates (by 2.0-fold), but enhanced factor XII and plasminogen hydrolysis (7.7- and 1.4-fold, respectively). The second-order rate constants for inhibition of huPK by antithrombin and C1-inhibitor were 2.40x10(2) M-1 s-1 and 1.70x10(4) M-1 s-1, respectively. Heparin improved the inhibition of huPK by these inhibitors (3.4- and 1.4-fold). Despite the fact that huPK was able to bind to a heparin-Sepharose matrix, its secondary structure was not modified by heparin, as monitored by circular dichroism. These actions may have a function in the control or maintenance of some pathophysiological processes in which huPK participates.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16895484     DOI: 10.1515/BC.2006.139

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  5 in total

1.  Factor XI anion-binding sites are required for productive interactions with polyphosphate.

Authors:  Y Geng; I M Verhamme; S A Smith; Q Cheng; M Sun; J P Sheehan; J H Morrissey; D Gailani
Journal:  J Thromb Haemost       Date:  2013-11       Impact factor: 5.824

2.  Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins.

Authors:  Boyangzi Li; Jiraporn Suwan; Jeffrey G Martin; Fuming Zhang; Zhenqing Zhang; Debra Hoppensteadt; Melanie Clark; Jawed Fareed; Robert J Linhardt
Journal:  Biochem Pharmacol       Date:  2009-04-21       Impact factor: 5.858

3.  Crystal Structure of Crataeva tapia Bark Protein (CrataBL) and Its Effect in Human Prostate Cancer Cell Lines.

Authors:  Rodrigo da Silva Ferreira; Dongwen Zhou; Joana Gasperazzo Ferreira; Mariana Cristina Cabral Silva; Rosemeire Aparecida Silva-Lucca; Reinhard Mentele; Edgar Julian Paredes-Gamero; Thiago Carlos Bertolin; Maria Tereza Dos Santos Correia; Patrícia Maria Guedes Paiva; Alla Gustchina; Alexander Wlodawer; Maria Luiza Vilela Oliva
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

4.  The involvement of proteoglycans in the human plasma prekallikrein interaction with the cell surface.

Authors:  Camila Lopes Veronez; Fabio D Nascimento; Katia R B Melo; Helena B Nader; Ivarne L S Tersariol; Guacyara Motta
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

5.  The Plant Proteinase Inhibitor CrataBL Plays a Role in Controlling Asthma Response in Mice.

Authors:  Anelize Sartori Santos Bortolozzo; Adriana Palmeira Dias Rodrigues; Fernanda Magalhães Arantes-Costa; Beatriz Mangueira Saraiva-Romanholo; Flávia Castro Ribas de Souza; Thayse Regina Brüggemann; Marlon Vilela de Brito; Rodrigo da Silva Ferreira; Maria Tereza Dos Santos Correia; Patrícia Maria Guedes Paiva; Carla Máximo Prado; Edna Aparecida Leick; Maria Luiza Vilela Oliva; Milton de Arruda Martins; Viviane Christina Ruiz-Schutz; Renato Fraga Righetti; Iolanda de Fátima Lopes Calvo Tibério
Journal:  Biomed Res Int       Date:  2018-10-01       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.